TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8667133

Group type: COMPARATOR
Intervention: Control group, no irrigation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline group, irrigation with 2 cc of 0.85% saline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tetracycline group, irrigation with 2 cc of aqueous tetracycline HCl, 50 mg/ml (5%)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Chlorhexidine group, irrigation with 2 cc of chlorhexidine
Number of subjects: 6
Study: 1536698

Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 0
Study: 6697280

Group type: EXPERIMENTAL
Intervention: Educational package on hypertension
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no educational package)
Number of subjects: 56
Study: 30992093

Group type: EXPERIMENTAL
Intervention: ACT-based lifestyle modification treatment
Number of subjects: 6
Study: 28629828

Group type: EXPERIMENTAL
Intervention: Operative procedures for proximal femoral bone metastasis (osteosynthetic devices vs. prosthetic replacement)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prosthesis treatment
Number of subjects: 26
Study: 26519020

Group type: EXPERIMENTAL
Intervention: Exercise intervention (walking and running for 25 minutes twice/week for 10 weeks at intensity corresponding to individual's ventilatory threshold)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (sedentary employees before intervention)
Number of subjects: 56
Study: 24004475

Group type: EXPERIMENTAL
Intervention: Web-based patient activation intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control condition (preventive services questions)
Number of subjects: 500
Study: 21664155

Group type: EXPERIMENTAL
Intervention: 1.3% NaOCl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.6% NaOCl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.3% NaOCl and 2.6% NaOCl
Number of subjects: 30
Study: 18243407

Group type: COMPARATOR
Intervention: Vinorelbine (V)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus Cisplatin (VP)
Number of subjects: 65
Study: 17070148

Group type: EXPERIMENTAL
Intervention: Abciximab bolus-only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abciximab bolus plus infusion
Number of subjects: 0
Study: 12854176

Group type: EXPERIMENTAL
Intervention: Heparin/low molecular weight heparin (LMWH) treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Regular treatment
Number of subjects: 52
Study: 11043809

Group type: EXPERIMENTAL
Intervention: Kampo kami-shoyo-san (TJ-24)
Number of subjects: 8
Study: 9261326

Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.5% ophthalmic solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: control vehicle drops
Number of subjects: 100
Study: 8489449

Group type: EXPERIMENTAL
Intervention: PhXA41 (0.006% solution, approximately 2 micrograms per treatment)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3549966

Group type: EXPERIMENTAL
Intervention: Six-month educational program provided by a nurse practitioner
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Recipients with strong social supports
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 170
Study: 2812914

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (80 mg/kg body weight, intramuscularly, once daily for 5 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Chloramphenicol (50 to 100 mg/kg body weight, orally, divided into 4 doses for 3 weeks)
Number of subjects: 59
Study: 29574484

Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg, once daily)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 29027715

Group type: EXPERIMENTAL
Intervention: HE4
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: CA125
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ROMA
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: CPH‐I
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: RMI
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: MI
Number of subjects: 164
Study: 26605928

Group type: EXPERIMENTAL
Intervention: Progesterone (400 mg vaginal suppositories, twice daily)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Placebo (matched vaginal suppositories)
Number of subjects: 836
Study: 23187965

Group type: EXPERIMENTAL
Intervention: Teduglutide (10 mg, subcutaneously administered)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy subjects aged <65 years
Number of subjects: 36
Study: 21560157

Group type: EXPERIMENTAL
Intervention: Perineal surface electromyography (EMG) during filling and voiding phases
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Preoperative EMG activity
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Subjects with neither abdominal straining during void nor interrupted flow
Number of subjects: 655
Study: 18478093

Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib‐MenAC vaccine
Number of subjects: 280

Group type: COMPARATOR
Intervention: DTPw‐HBV/Hib vaccine
Number of subjects: 280
Study: 16525624

Group type: EXPERIMENTAL
Intervention: Paste zinc oxide‐eugenal
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Vitapex
Number of subjects: 283
Study: 15532520

Group type: EXPERIMENTAL
Intervention: Transformational leadership style
Number of subjects: 266

Group type: COMPARATOR
Intervention: Transactional leadership style
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Private hospitals
Number of subjects: 266

Group type: COMPARATOR
Intervention: Public hospitals
Number of subjects: 266
Study: 11240031

Group type: COMPARATOR
Intervention: Circulating levels of soluble forms of adhesion molecules (sICAM-1 and sVCAM-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attachment capacities of circulating lymphocytes to rICAM-1 and rVCAM-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibronectin-penetrating capacities of circulating lymphocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cellular concentrations of MMP-9 in circulating lymphocytes
Number of subjects: 0
Study: 9210689

Group type: EXPERIMENTAL
Intervention: Cefdinir (300 mg twice daily for 10 days)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Cefaclor (500 mg three times daily for 10 days)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 690

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 690
Study: 7968751

Group type: EXPERIMENTAL
Intervention: Mail-out intervention
Number of subjects: 342

Group type: COMPARATOR
Intervention: Advice from GP
Number of subjects: 342

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 342
Study: 3614956

Group type: EXPERIMENTAL
Intervention: 0.11 mg/kg diazepam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.66 microgram/kg fentanyl
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of diazepam and fentanyl doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29268206

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) 10000lx
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dim light (DL, < 500lx)
Number of subjects: 32
Study: 27282265

Group type: EXPERIMENTAL
Intervention: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group)
Number of subjects: 501

Group type: COMPARATOR
Intervention: 40 mg esomeprazole daily (monotherapy group)
Number of subjects: 501
Study: 24955584

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 63
Study: 23301435

Group type: EXPERIMENTAL
Intervention: Culturally tailored educational intervention designed to build family capacity
Number of subjects: 29

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 29
Study: 20093623

Group type: EXPERIMENTAL
Intervention: Red wine (RW) 100 mL daily for 3 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Water (100 mL) daily for 3 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Beer (250 mL) daily for 3 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vodka (30 mL) daily for 3 weeks
Number of subjects: 80
Study: 18565159

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study: 16195036

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Physical activity and ibuprofen (combination)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study: 12555175

Group type: EXPERIMENTAL
Intervention: Plugged group (n = 128)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Unplugged group (n = 134)
Number of subjects: 262
Study: 11200349

Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: PTA followed by Palmaz stents
Number of subjects: 141
Study: 9863122

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine of replenishing Qi and nourishing Yin (RQNY) combined with a small dosage of Tapazol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tapazol alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination therapy (TCM + Tapazol)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Western medicine (Tapazol)
Number of subjects: 42
Study: 8512760

Group type: EXPERIMENTAL
Intervention: 1% w/v cyclopentolate hydrochloride
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: cyclopentolate polygalacturonate in saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: cyclopentolate polygalacturonate in acetate buffer
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: cyclopentolate polygalacturonate
Number of subjects: 8
Study: 3815397

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral (PO) 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) 5 mg
Number of subjects: 0
Study: 31099033

Group type: EXPERIMENTAL
Intervention: VCAP-AMP-VECP in low-risk group
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: VCAP-AMP-VECP in intermediate-risk group
Number of subjects: 105

Group type: COMPARATOR
Intervention: CHOP-14 in intermediate-risk group
Number of subjects: 105
Study: 28860165

Group type: EXPERIMENTAL
Intervention: Nutrient ingestion (essential amino acids and maltodextrin)
Number of subjects: 12
Study: 25754458

Group type: EXPERIMENTAL
Intervention: Midurethral sling (MUS)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (prolapse repair only)
Number of subjects: 134
Study: 23764005

Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 IU/kg once daily for 6 months
Number of subjects: 900

Group type: COMPARATOR
Intervention: Initial tinzaparin 175 IU/kg once daily for 5-10 days and dose-adjusted warfarin (target INR 2.0-3.0) for 6 months
Number of subjects: 900
Study: 20978642

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: One‐Up Bond F (OB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ultrasound diamond bur (UB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional diamond bur (CB)
Number of subjects: 20
Study: 19265308

Group type: EXPERIMENTAL
Intervention: Hand acupuncture therapy (including hand acupuncture and press-pellets based on corresponding points)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 16325440

Group type: EXPERIMENTAL
Intervention: Inhalation of racemic albuterol from dry powder inhalers
Number of subjects: 0
Study: 14696127

Group type: COMPARATOR
Intervention: Leisure-time physical activity (light)
Number of subjects: 29133

Group type: COMPARATOR
Intervention: Leisure-time physical activity (moderate)
Number of subjects: 29133

Group type: COMPARATOR
Intervention: Leisure-time physical activity (heavy)
Number of subjects: 29133

Group type: COMPARATOR
Intervention: Occupational physical activity
Number of subjects: 29133
Study: 11726410

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 6 mg
Number of subjects: 0
Study: 9743164

Group type: EXPERIMENTAL
Intervention: Maxair Autohaler (1,200 microg pirbuterol) plus saline solution by nebulizer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo by Autohaler plus 2,500 microg albuterol via nebulizer
Number of subjects: 24
Study: 7522415

Group type: EXPERIMENTAL
Intervention: Neoadjuvant total androgen ablation therapy (3 months of goserelin acetate and flutamide)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Hormonally untreated, grade-matched prostatic adenocarcinomas (control)
Number of subjects: 27
Study: 3381269

Group type: EXPERIMENTAL
Intervention: Cyclopsorine A (CsA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy (corticosteroids/Leukeran)
Number of subjects: 40
Study: 31143777

Group type: EXPERIMENTAL
Intervention: 4% Niacinamide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.05% Retinoic Acid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28684357

Group type: EXPERIMENTAL
Intervention: A‐Helping‐Hand (AHH) intervention with 6 weekly psychoeducational sessions and boosters
Number of subjects: 348

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 348
Study: 24997645

Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine
Number of subjects: 3046

Group type: COMPARATOR
Intervention: High-dose radioiodine
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine (pT2-4 cancer)
Number of subjects: 3046

Group type: COMPARATOR
Intervention: High-dose radioiodine (pT2-4 cancer)
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine (total thyroidectomy)
Number of subjects: 3046

Group type: COMPARATOR
Intervention: High-dose radioiodine (total thyroidectomy)
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine (thyrotropin α stimulation)
Number of subjects: 3046

Group type: COMPARATOR
Intervention: High-dose radioiodine (thyrotropin α stimulation)
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: Moderate-dose radioiodine
Number of subjects: 3046
Study: 24099279

Group type: EXPERIMENTAL
Intervention: GDC-0941 (fasted)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GDC-0941 (high-fat meal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabeprazole + GDC-0941 (fasted)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabeprazole + GDC-0941 (high-fat meal)
Number of subjects: 0
Study: 20848317

Group type: EXPERIMENTAL
Intervention: Adeno-tonsillectomy followed by rapid maxillary expansion (RME)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) followed by adeno-tonsillectomy
Number of subjects: 31
Study: 19366274

Group type: EXPERIMENTAL
Intervention: Frovatriptan once daily (day 1: 5 mg; days 2-6: 2.5 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Frovatriptan twice daily (day 1: 5 mg [10 mg total]; days 2-6: 2.5 mg [5 mg total])
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both dosing regimens
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: ECC users
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-ECC users
Number of subjects: 26
Study: 16709697

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 15290418

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) + noradrenaline (5 micro g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline alone (Control)
Number of subjects: 30
Study: 11250190

Group type: EXPERIMENTAL
Intervention: Warm intermittent antegrade blood cardioplegia (37 degrees C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cold intermittent antegrade blood cardioplegia (4 degrees C)
Number of subjects: 30
Study: 8988994

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Acute hypervolemic hemodilution (HHD)
Number of subjects: 49
Study: 8548967

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms b.i.d. for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 100 micrograms q.i.d. for 6 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 40
Study: 2364464

Group type: EXPERIMENTAL
Intervention: Jiedu Yanggan Gao (OG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Three charred medicinal herbs (CG)
Number of subjects: 96
Study: 385457

Group type: EXPERIMENTAL
Intervention: pepstatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 31884409

Group type: EXPERIMENTAL
Intervention: Oronasal mask (ONM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nasal mask (NM)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nasal mask combined with oral shield device (NMS)
Number of subjects: 29
Study: 30689671

Group type: EXPERIMENTAL
Intervention: Mass azithromycin distribution strategies for trachoma elimination
Number of subjects: 988
Study: 28421656

Group type: EXPERIMENTAL
Intervention: Boesenbergia pandurata ethanol extract (BPE) containing 8% of panduratin A
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 25817067

Group type: EXPERIMENTAL
Intervention: Unpredictable shocks (unpredictability group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked shocks (predictability group)
Number of subjects: 0
Study: 24102972

Group type: EXPERIMENTAL
Intervention: Dietary changes (reduction in energy, fat, and sodium intake; increase in fruit, vegetable, and fibre intake)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Increased fruit intake
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Increased vegetable intake
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Reductions in fat, energy, and sodium intake
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Plasma vitamin C increase
Number of subjects: 736
Study: 22331175

Group type: EXPERIMENTAL
Intervention: Melatonin (4 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 20192884

Group type: EXPERIMENTAL
Intervention: Prospective quality control system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17616259

Group type: EXPERIMENTAL
Intervention: THEME (Update day plus 12 weekly worksheets, feedback to audiotaped sessions, and three 30 minute sessions of telephone coaching)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (Update day in MI)
Number of subjects: 54
Study: 16157230

Group type: EXPERIMENTAL
Intervention: Behavioral interventions for heroin and cocaine dependence
Number of subjects: 286
Study: 12377405

Group type: EXPERIMENTAL
Intervention: Nicotine 21 mg transdermal patch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo transdermal patch
Number of subjects: 30
Study: 10203379

Group type: EXPERIMENTAL
Intervention: Interleukin (IL)‐2 therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (HAART only)
Number of subjects: 0
Study: 8880837

Group type: EXPERIMENTAL
Intervention: Inflammatory mediators (IM) injected in acidic solution (BK, 5-HT, HIS, PGE2) at concentrations of 10(-7) M, 10(-6) M, and 10(-5) M.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Plain phosphate buffer (pH 5.2) injected into acidotic skin after IM application.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Negative control: IM in neutral solution injected into normal skin continuously infiltrated with buffer solution at pH 7.4.
Number of subjects: 6
Study: 1947601

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (96 meq/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study: 6341388

Group type: EXPERIMENTAL
Intervention: Orbital cobalt irradiation combined with systemic 6 alpha‐methylprednisolone (methylprednisolone)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Systemic methylprednisolone alone
Number of subjects: 48
Study: 30808321

Group type: EXPERIMENTAL
Intervention: LTOT 24 h/day
Number of subjects: 2126

Group type: COMPARATOR
Intervention: LTOT 15 h/day
Number of subjects: 2126
Study: 27146061

Group type: EXPERIMENTAL
Intervention: 14-session co-parent training groups (n=140 couples)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Minimal intervention control groups with referral to local services as necessary (n=69 couples)
Number of subjects: 209
Study: 26333474

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1005
Study: 23429588

Group type: EXPERIMENTAL
Intervention: treprostinil diolamine alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: sildenafil alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: combination treprostinil diolamine and sildenafil
Number of subjects: 18
Study: 21153444

Group type: EXPERIMENTAL
Intervention: Decomposable idioms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predicative metaphors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control expressions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identity priming for idiomatic expressions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identity priming for metaphor expressions
Number of subjects: 0
Study: 19216796

Group type: EXPERIMENTAL
Intervention: Preformed teams
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ad-hoc teams
Number of subjects: 100
Study: 17320023

Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin D
Number of subjects: 0
Study: 14992978

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1 Hz rTMS
Number of subjects: 24